Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

The Clinical Trial Vanguard
clinicaltrialvanguard.com > news > sunshine-guojian-posts-95-profit-growth-with-two-nmpa-drug-approvals

Sunshine Guojian Posts 95% Profit Growth With Two NMPA Drug Approvals

44+ min ago   (432+ words) The Clinical Trial Vanguard Sunshine Guojian Posts 95% Profit Growth With Two NMPA Drug Approvals Net profit nearly doubling, up 95% year-on-year to RMB 371 million, is the kind of number that reframes a company’s story. Sunshine Guojian’s 2026 interim results show a business…...

Google News
clinicaltrialvanguard.com > news > citius-pharmaceuticals-reports-lymphir-revenue-growth-explores-car-t-combination

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

5+ day, 50+ min ago   (479+ words) The Clinical Trial Vanguard Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination An 86% objective response rate in a Phase 1 trial gets attention in any context, but the setting here sharpens the stakes considerably: LYMPHIR (denileukin diftitox-cxdl), approved in August…...